Literature DB >> 18057310

Bone and mineral guidelines for patients with chronic kidney disease: a call for revision.

Dennis L Andress1.   

Abstract

Recent clinical studies of mineral metabolism in patients with chronic kidney disease have helped to verify and extend the Kidney Disease Outcomes Quality Initiative practice guidelines for bone metabolism and disease that were published in 2003. In particular, investigations that examined calcium loading, vitamin D therapy, and mortality risk associated with serum calcium and phosphate in dialysis patients have been the most helpful clinically. As a consequence, there is now a growing interest to have the previous guidelines amended accordingly, which will be performed through the Kidney Disease: Improving Global Outcomes working group after a debate within the nephrology community. The new data support this call for revision in an attempt to improve survival of the dialysis patient by emphasizing the importance of intravenous vitamin D therapy and of preventing excess calcium loading. These studies also suggest avenues for future investigation into nontraditional causes and treatments of cardiovascular disease in patients with chronic kidney disease.

Entities:  

Mesh:

Year:  2007        PMID: 18057310     DOI: 10.2215/CJN.01310307

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  5 in total

Review 1.  The virtues of vitamin D--but how much is too much?

Authors:  Rukshana Shroff; Craig Knott; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2010-09       Impact factor: 3.714

2.  Calcium absorption response to cholecalciferol supplementation in hemodialysis.

Authors:  Laura A G Armas; Mohsen Zena; Richard Lund; Robert P Heaney
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-14       Impact factor: 8.237

Review 3.  Vitamin D in chronic kidney disease.

Authors:  Yahn-Yir Chau; Juhi Kumar
Journal:  Indian J Pediatr       Date:  2012-04-29       Impact factor: 1.967

Review 4.  Kidney disease outcomes quality initiative guidelines for bone and mineral metabolism: emerging questions.

Authors:  Tejas V Patel; Ajay K Singh
Journal:  Semin Nephrol       Date:  2009-03       Impact factor: 5.299

5.  Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3-4: a preliminary study.

Authors:  Dimitrios Hadjiyannakos; Vassilis Filiopoulos; Sofia Trompouki; Makroui Sonikian; Ioannis Karatzas; Konstantinos Panagiotopoulos; Dimosthenis Vlassopoulos
Journal:  Clin Kidney J       Date:  2013-02-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.